6/28/23, 11:44 PM Omeprazole for peptic ulcer bleeding Pathway Feedback Search Clinical Topics Home Studies Omeprazole for peptic ulcer bleeding Omeprazole for peptic ulcer bleeding Disease Non-variceal upper gastrointesti Trial question What is the role of intravenous omeprazole in patients having undergone endoscopic treatment for bleeding peptic ulcers? Study design Single center Double blinded RCT Population Characteristics of study participants 33.0% female N = 240 67.0% male 240 patients (80 female, 160 male) Inclusion criteria: patients having undergone endoscopic treatment for bleeding peptic ulcers Key exclusion criteria: unsuccessful endoscopic treatment, terminal cancer, moribund state, or unwilling to provide consent Interventions N=120 omeprazole (as a bolus intravenous injection of 80 mg followed by an infusion of 8 mg per hour for 72 hours) N=120 placebo (matching placebo IV for 72 hours) Primary outcome https://web.pathway.md/studies/reczNULibBvVNbbXA 1/2 6/28/23, 11:44 PM Omeprazole for peptic ulcer bleeding Pathway Rate of bleeding recurrence within 30 days 22.5 % 22.5 16.9 % 11.3 % Significant decrease 6.7 5.6 % NNT = 6 0.0 % Omeprazole Placebo Significant decrease in the rate of bleeding recurrence within 30 days (6.7% vs. 22.5%; HR 0.25, 95% CI 0.11 to 0.58) Secondary outcomes Borderline significant decrease in death at 30 days (4.2% vs. 10%; RR 0.42, 95% CI -0.12 to 0.96) Conclusion In patients having undergone endoscopic treatment for bleeding peptic ulcers, omeprazole was superior to placebo with respect to the rate of bleeding recurrence within 30 days. Reference Lau JY, Sung JJ, Lee KK et al. Effect of intravenous omeprazole on recurrent bleeding after endoscopic treatment of bleeding peptic ulcers. N Engl J Med. 2000 Aug 3;343(5):310-6. Open reference URL https://web.pathway.md/studies/reczNULibBvVNbbXA 2/2